February 25, 2022 7:53am
Yesterday, Thursday had the Nasdaq turning a 3.5% loss into 3.3% gain – this isn’t the end of revolutions
Pre-open indications: 5 BUY 3 SELL Indications and 1 pimp/pump/promote
RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.
Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.
Only the facts … I ask questions and note the indications of what could happen …
Dow futures are UP +0.11% (+38 points), S&P futures are UP +0.12% (+5 points) and NASDAQ futures are UP +0.25% (+35 points)
Indexes futures were falling and then split to the upside onFriday morning as Russia closes in on the Ukrainian capital of Kyiv,
European stocks were higher, tracking a fragile global rebound,
Asia-Pacific shares mostly rose appearing to ignore Russia’s attack on Ukraine but not the +2% rise in oil,
Henry’omics:
Geo-politics are the number #1 topic leading capital markets and then we have Fed Chair Powell.
All three averages are "flip/flopping" in correction territory, or down 10% or more from their respective record highs. The Nasdaq opened Thursday’s session in bear market territory, down more than 20% from its record high in November. <CNBC>
Are we seeing a repeat of history?
· Global oil benchmark Brent crude gained 2.3% to settle at $99.08 per barrel, after hitting the $100 level for the first time since 2014. The U.S. oil benchmark, WTI, settled the day 71 cents, or 0.77%, higher at $92.81 per barrel.
RegMed Investors’ (RMi) closing bell: “a lot of buys on first day of a disclosed Ukraine attack as Nasdaq reverses higher in a sigh of cell and gene therapy sector oversold relief” … https://www.regmedinvestors.com/articles/12315
Ebb and flow –
· February stats: 11 negative and 6 positive closes
· January stats: 1 holiday, 1 neutral, 13 negative and 6 positive closes
RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628 ... added (NTLA), (SAGE), (IONS), (SAGE), (SGMO), (VCEL) and (EDIT) -yesterday’s total was 11 to date
The Biostage (OTC: QB: BSTG) Chronicles: Who, What, When, Where, Why and one H (HOW) … https://www.regmedinvestors.com/articles/12306
Companies in my headlights – It’s your decision; I provide ideas and context:
SELL indications:
Editas Medicine (EDIT closed -$0.60) morning indication: -$0.05 or -0.32%
Sage Therapeutics (SAGE +$2.10) -$0.05 or -0.14%
ReNeuron (RENE.L +$1.50) -0.15 or -0.48%
BUY Indications:
UniQure NV (QURE closed +$0.34) morning indication: +$0.32 or +2%
bluebird bio (BLUE +$3.91) +$0.39 or +6.32%
CRISPR Therapeutics (CRSP -$3.91) +$0.34 or +0.59%
Global Blood Therapeutics (GBT +$1.42) +$0.80 or +2.65%
Sangamo Therapeutics (SGMO +$0.33) +$0.28 or +4.90%
Pimp/Pump and Promote:
Biostage (OTCQB: BSTG) closed down -$0.62 with a “sudden block” of 1,259 share traded after Wednesday’s +$0.20 with an “out-of-the air” block of 3,070 after Tuesday’s +$0.62 with 4,225 shares traded
WHO is BUYING these shares of a company with a 2-year-old IND, NO clinical trial initiation, a terminal death lawsuit overhang and a dwindling cash position?
· Also, by use of the pump/promote process; is BSTG preparing to register the outstanding private placement (PP) shares for a reverse to initiate an offering - they’re NOT going ANYWHERE without a cash inflow.
The BOTTOM LINE: I was actually surprised by the sector’s upside reaction, buying on the attack.
One question is asked: are markets and our sector more afraid of Fed Chair Powell autocracy or Putin’s ambition?
Amid the bedlam taking place in Europe, it’s easy to lose sight of the fact that demand in the U.S. largest economy remains strong enough to keep inflation growth uncomfortably elevated.
The risk is will Fed Chair Powell be another trigger-happy policy autocrat at the central bank’s next meeting.
Fed policy is the subtext of virtually every discussion about the market’s direction; we will always have sector earnings.
To add to the chaos and uncertainty, this week had “heavy” earnings reporting
Earnings’ reporting on the horizon:
· Fate Therapeutics, Monday, 2/28
· BioLife Solutions (BLFS), Monday,2/28
· Athersys (ATHX), Tuesday, 3/15
Investors should focus on forward-looking guidance, last year’s operating losses i.e., spending and cash positions or runways!
RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
WHY do I keep reporting on Biostage (BSTG): I WAS there to experience what occurred and saw the decay of transparency and more; it takes courage, resolve and patience to stay the course of asking the questions without response!
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider their investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in FATE, CRS, securities referred to in this publication.
